Prevention Of Decline in Cognition After Stroke Trial "PODCAST "

Active, not recruiting

Phase N/A Results N/A

Eligibility Criteria

Inclusion Criteria

Age greater than 70 years and telephone-administered mini-mental state examination (MMSE) greater than 16; or aged greater than 60 years and telephone-MMSE 17 - 19, either sex; Functionally independent (modified Rankin Scale [mRS] 0 - 2); Ischaemic stroke (any cortical Oxfordshire Community Stroke Project [OCSP]/Trial of ORG 10172 in Acute Stroke Treatment [TOAST] type) or primary intracerebral haemorrhage (cortical or basal ganglia); three to seven months post-event (to allow cognitive, neurological, blood pressure [BP] and lipid stabilisation, but avoid attrition); systolic BP 125 - 170 mmHg; total cholesterol 3 - 8 mmol/l; presence of a reporter: partner, sibling, child, friend (for Informant Questionnaire of Cognitive Decline[IQCODE]/Dementia Quality of Life [DEMQoL]).

Exclusion Criteria

Participants not meeting inclusion criteria; Subarachnoid haemorrhage; secondary intracranial haemorrhage (trauma, arteriovenous malformation [AVM], cavernoma); posterior circulation ischaemic stroke; posterior circulation haemorrhage; no computed tomography (CT)/magnetic resonance imaging (MRI) during index stroke; inability to give consent or do study measures, e.g. severe dysphasia, weakness of dominant arm; severe hypertension (systolic BP greater than 170 mmHg); definite need for 'intensive' BP control; severe hypercholesterolemia (total cholesterol [TC] greater than 8 mmol/l); definite need for 'high intensity' statin or ezetimibe; definite need for a cholinesterase inhibitor; familial stroke associated with dementia, e.g. cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL); chronic renal failure: glomerular filtration rate (GFR) less than 50; liver disease, alanine aminotransferase (ALT) greater than 60; ongoing participation in trials involving drug and/or devices, or within the last 3 months.